IL145720A0 - Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids - Google Patents

Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids

Info

Publication number
IL145720A0
IL145720A0 IL14572000A IL14572000A IL145720A0 IL 145720 A0 IL145720 A0 IL 145720A0 IL 14572000 A IL14572000 A IL 14572000A IL 14572000 A IL14572000 A IL 14572000A IL 145720 A0 IL145720 A0 IL 145720A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
vinca alkaloids
containing liposome
mol
Prior art date
Application number
IL14572000A
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of IL145720A0 publication Critical patent/IL145720A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Liposome-encapsulated vincristine is provided for treating a cancer such as a lymphoma, leukaemia or myeloma and especially non-Hodgkin's Lymphoma or Acute Lymphocytic Leukaemia. The liposomes comprise sphingomyelin and cholesterol in a ratio between 75/25 (mol % sphingomyelin/mol % cholesterol) and 50/50 (mol % sphingomyelin/mol % cholesterol) and vincristine at a concentration of 0.1 to 0.5 mg/ml.
IL14572000A 1999-04-01 2000-03-31 Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids IL145720A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02
PCT/US2000/008669 WO2000059473A1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Publications (1)

Publication Number Publication Date
IL145720A0 true IL145720A0 (en) 2002-07-25

Family

ID=26825635

Family Applications (4)

Application Number Title Priority Date Filing Date
IL14572000A IL145720A0 (en) 1999-04-01 2000-03-31 Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids
IL145720A IL145720A (en) 1999-04-01 2001-09-30 Use of a liposome encapsulated vincristine for the preparation of a pharmaceutical composition for treating cancer
IL212389A IL212389A (en) 1999-04-01 2011-04-14 Compositions comprising liposome-encapsulated vincristine for use in treating cancer
IL212390A IL212390A (en) 1999-04-01 2011-04-14 Compositions comprising liposome-encapsulated vincristine for use in treating cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL145720A IL145720A (en) 1999-04-01 2001-09-30 Use of a liposome encapsulated vincristine for the preparation of a pharmaceutical composition for treating cancer
IL212389A IL212389A (en) 1999-04-01 2011-04-14 Compositions comprising liposome-encapsulated vincristine for use in treating cancer
IL212390A IL212390A (en) 1999-04-01 2011-04-14 Compositions comprising liposome-encapsulated vincristine for use in treating cancer

Country Status (14)

Country Link
EP (3) EP1169021B1 (en)
JP (3) JP2002541088A (en)
AT (1) ATE442839T1 (en)
AU (1) AU777572B2 (en)
BR (1) BRPI0009448B8 (en)
CA (1) CA2366787C (en)
CY (1) CY1109641T1 (en)
DE (1) DE60042968D1 (en)
DK (2) DK2266537T3 (en)
ES (2) ES2524141T3 (en)
HK (1) HK1152246A1 (en)
IL (4) IL145720A0 (en)
PT (1) PT1169021E (en)
WO (1) WO2000059473A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0009448B8 (en) * 1999-04-01 2021-05-25 Univ Texas kit for use in treating a neoplasm in a mammal
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2002312777B2 (en) * 2001-03-27 2007-07-05 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
WO2003097052A2 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
FR2840203B1 (en) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P ORAL PHARMACEUTICAL COMPOSITION FOR SOFT CAPSULES CONTAINING VINORELBINE AND METHOD OF TREATMENT
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
RU2394596C2 (en) * 2004-07-09 2010-07-20 Байер Шеринг Фарма Акциенгезельшафт Combined therapy by radioactively marked antibody anti-cd20 in treatment of b-cellular lymphoma
DK1781255T3 (en) * 2004-08-10 2012-05-29 Talon Therapeutics Inc Compositions and Methods for Treating Leukemia
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
JP2012506428A (en) * 2008-10-24 2012-03-15 グルオウセステル プハルマセウトイカルス Cancer therapy
TR201908531T4 (en) * 2012-11-20 2019-08-21 Arbutus Biopharma Corp ADVANCED METHOD FOR PREPARATION OF LIPOSOME CAPSULATED VINCRYSTINE FOR THERAPEUTIC USE
WO2014116866A1 (en) * 2013-01-24 2014-07-31 Memorial Sloan Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
BR112015025347A2 (en) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetyl naphtho [2-3-b] furan-4,9-dione for use in cancer treatment
TWI678213B (en) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 A ready-to-use formulation for vincristine sulfate liposome injection
JP7106563B2 (en) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Naphthofuran derivatives, their preparation and methods of use
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BRPI0009448B8 (en) * 1999-04-01 2021-05-25 Univ Texas kit for use in treating a neoplasm in a mammal

Also Published As

Publication number Publication date
AU4060600A (en) 2000-10-23
HK1152246A1 (en) 2012-02-24
BRPI0009448B1 (en) 2018-09-11
IL212390A0 (en) 2011-06-30
EP2266537A2 (en) 2010-12-29
JP2012158602A (en) 2012-08-23
IL212389A0 (en) 2011-06-30
EP2266537A3 (en) 2012-02-22
DK1169021T3 (en) 2010-01-11
EP1985285A3 (en) 2009-08-12
CY1109641T1 (en) 2014-08-13
ATE442839T1 (en) 2009-10-15
IL212389A (en) 2015-07-30
PT1169021E (en) 2009-11-18
WO2000059473A1 (en) 2000-10-12
CA2366787C (en) 2013-03-12
AU777572B2 (en) 2004-10-21
DE60042968D1 (en) 2009-10-29
EP1169021B1 (en) 2009-09-16
IL145720A (en) 2011-05-31
EP2266537B1 (en) 2014-09-03
JP2015071631A (en) 2015-04-16
EP1169021A1 (en) 2002-01-09
CA2366787A1 (en) 2000-10-12
JP5981214B2 (en) 2016-08-31
BR0009448A (en) 2002-01-08
JP2002541088A (en) 2002-12-03
ES2333400T3 (en) 2010-02-22
DK2266537T3 (en) 2014-12-15
EP1985285A2 (en) 2008-10-29
BRPI0009448B8 (en) 2021-05-25
ES2524141T3 (en) 2014-12-04
IL212390A (en) 2014-08-31

Similar Documents

Publication Publication Date Title
IL145720A0 (en) Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids
PL319833A1 (en) Compounds and composition for carrying active media
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
BG103417A (en) Condensed pyrimidine bicyclic derivatives
HK1012268A1 (en) Composition containing cisplatin and topotecan as antitumor agent
PL341054A1 (en) Novel suppositiories containing an active compound being unstable in acid environments
LU90856I2 (en) Uprima - apomorphine hydrochloride and its pharmaceutically acceptable derivatives
MX9602683A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances.
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
UA72881C2 (en) Thienopyrimidine and derivatives of thienopyrimidine as anticancer agents
WO1999043355A3 (en) Formulations containing oxaliplatin
MX9605023A (en) Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances.
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
HU9600360D0 (en) New bis-naphthalimides for the treatment of cancer
GB9522885D0 (en) Improvements in or relating to organic compositions
AU576914B2 (en) 5-cyanopyridine-2-diazohydroxide, basic salts thereof
ES8601200A1 (en) 3-Haloethyl-4-oxopyrazolo (5,1-d)-1,2,3,5-tetrazine-8-carboxamide and process for their production and use.
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
GB9308111D0 (en) Active compound from a stonge
AU578125B2 (en) Pyrazine diazohydroxide compounds
MY133596A (en) Compound and method for the treatment of pain
MX9703839A (en) Lubeluzole intravenous solutions.
NZ507349A (en) Spisulosine Compounds having antitumour activity